Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

NCT00759200 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

525

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: alb-interferon alfa 2b
DRUG: alb-interferon alfa 2b
DRUG: alb-interferon alfa 2b
DRUG: alb-interferon alfa 2b
DRUG: peg-interferon

Sponsor

Novartis

Collaborators

[object Object]